Bioanalytics
James Huleatt, PhD (he/him/his)
Bioassay Development Lead
Bill & Melinda Gates Medical Research Institute
Cambridge, Massachusetts
Dawn Dufield, PhD
Scientific Officer, Mass Spectrometry
KCAS
Olathe, Kansas
This presentation will discuss hybrid LC-MS/MS technologies and give some perspectives on when is Hybrid the best choice over more traditional LBA approaches. The advantages and disadvantages of each technology will be briefly discussed as well as what questions to ask to help choose the best or appropriate technology. This idea will be emphasized through the presentation of multiple case studies starting with a simple generic Mab to several more complicated ones on various ADC's, where multiple assays are needed such as total Ab, ADC and free payload. The ADC case studies will show several strategies that can be utilized depending on the type of ADC and information needed as well as what reagents are available. For example, when there is a cleavable linker or lack of anti-payload antibodies. Other examples will show how to apply the generic LCMS assay concept to a more generic ADC screen for stability or PK analysis. Additional multiplexing assays will be highlighted including proteins/biomarker that have no available protein standard and how to approach that situation. It will be emphasized that it is important to think outside the box and evaluate each project holistically to ensure we are finding the best solutions for each situation.